A young woman with breast cancer was experiencing such intense hot flashes ... Her oncologist, Ramy Sedhom, MD, suggested she ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Scientists also revealed that circular fragments of DNA called extrachromosomal DNA (ecDNA) is a significant source of drug ...

With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...

When it comes to cancer symptoms, we are often given advice on which signs to look out for. However, there is a type of ...

Research and development expenses for the third quarter of 2024 increased to $8.1 million from $6.2 million for the prior ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds.

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after treatment ends, according to the largest comprehensive analysis reporting ...

with less than 10% Grade 1 and no Grade 2 or higher drug-related adverse events reported. No serious adverse events have been reported. Future Development: The Company plans to continue development of ...

In a report released today, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Tyra Bioscience (TYRA – Research Report), ...